Inspire Corporate Bond ETF (IBD)
ARCA ARCA Primary 
Gold Stocks Steal The Luster In IBD Growth List; These Stocks Stand Out
Gold stock Agnico Eagle Mines has passed a buy point and outperformed the S&P 500. Other gold stocks have entered the IBD 50.
GE, IBD's Stock Of The Day, Doubles Investments In U.S. Factories
GE Aerospace doubling investments in U.S. factories with commercial and military jet-engine deliveries set to grow. The post GE, IBD's Stock Of The Day, Doubles Investments In U.S. Factories appeared first on Investor's Business Daily.
Spyre Therapeutics: Targeting The Future Of IBD Treatment
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis.
Nvidia Earnings Preview: Blackwell, DeepSeek And Big Expectations | Earnings Cheat Sheet | IBD
IBD's Alissa Coram and Ed Carson preview key upcoming earnings reports from Nvidia, Axon and Cava. Check out our daily newsletter!
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst David Amsellem reiterated the Overweight rating on Teva Pharmaceutical Industries Limited TEVA with a price forecast of $30.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva appeared first on Investor's Business Daily.
Carpenter Technology Stock Receives IBD Stock Rating Upgrade
Carpenter Technology saw its IBD SmartSelect Composite Rating jump to 96 Thursday, up from 94 the day before. The post Carpenter Technology Stock Receives IBD Stock Rating Upgrade appeared first on Investor's Business Daily.
IBD Sector Leader Breaks Out On First China Policy Shift In 14 Years
Sector leader Atour Lifestyle has been riding the China stimulus wave as it hovers near a buy point and all-time high. The post IBD Sector Leader Breaks Out On First China Policy Shift In 14 Years appeared first on Investor's Business Daily.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points
Meta stock and Nvidia peer Broadcom are among among five S&P 500 stocks on IBD Leaderboard that are near buy points. The post Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points appeared first on Investor's Business Daily.
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's Disease and Ulcerative Colitis. The Crohn's Disease treatment market is projected to reach a value of $17.80 billion by 2033.
